| pathology | Demonstrated benefit and harm | k | | | |
|---|
| diabetes type 2 | versus angiotensin-converting enzyme inhibitors No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ABCD (hypertension), 1998 | nisoldipine vs enalapril | Fatal and nonfatal MI 5.00 [1.95; 12.84] Cardiovascular events 0.43 [0.25; 0.73] | | All deaths 0.77 [0.36; 1.65] Cardiovascular death 2.00 [0.69; 5.76] Stroke 1.57 [0.62; 3.98] |
| Trial | Treatments | Patients | Method |
|---|
| ABCD (hypertension), 1998 | nisoldipine (long acting) (n=235) vs. enalapril (n=235) | patients with non-insulin-dependent diabetes and hypertension | Double blind Factorial plan Sample size: 235/235 Primary endpoint: 24-hour creatinine clearance FU duration: 5 y |
|
| heart failure | versus placebo or no treatment No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Nisoldipine vs placebo | | | | | nisoldipine vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Gaudron, 1996 | Nisoldipine (n=-9) vs. placebo (n=-9) | patients with congestive heart failure due to ischaemic heart disease, NYHA class II, FE<=45% | Sample size: -9/-9 Primary endpoint: FU duration: 18 months | | Rousseau, 1994 | nisoldipine 20 mg once daily (n=16) vs. placebo (n=16) | patients with congestive heart failure due to ischaemic heart disease, NYHA class II | Double blind Sample size: 16/16 Primary endpoint: myocardial perfusion and neuro-hormonal status FU duration: 2 months |
|
| heart failure | versus angiotensin-converting enzyme inhibitors No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| nisoldipine vs captopril | | | |
| Trial | Treatments | Patients | Method |
|---|
| Schofer, 1990 | nisoldipine (2 X 10 mg) (n=24) vs. captopril (3 X 25 mg) (n=0) | patients with congestive heart failure due to ischaemic heart disease, NYHA class II-III | Double blind Sample size: 24/0 Primary endpoint: haemodynamic response FU duration: 3 months |
|
| hypertension | versus angiotensin-converting enzyme inhibitors No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ABCD (hypertension), 1998 | nisoldipine vs enalapril | Fatal and nonfatal MI 5.00 [1.95; 12.84] Cardiovascular events 0.43 [0.25; 0.73] | | All deaths 0.77 [0.36; 1.65] Cardiovascular death 2.00 [0.69; 5.76] Stroke 1.57 [0.62; 3.98] |
| Trial | Treatments | Patients | Method |
|---|
| ABCD (hypertension), 1998 | nisoldipine (long acting) (n=235) vs. enalapril (n=235) | patients with non-insulin-dependent diabetes and hypertension | Double blind Factorial plan Sample size: 235/235 Primary endpoint: 24-hour creatinine clearance FU duration: 5 y |
|
| percutaneous coronary intervention | versus control or placebo No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Dens (CAPARES), 2000 | nisoldipine vs placebo | CABG 0.08 [0.01; 0.64] | | restenosis 0.89 [0.77; 1.03] death 2.19 [0.20; 24.09] AMI 0.44 [0.09; 2.25] re-PTCA 0.82 [0.65; 1.03] |
| Trial | Treatments | Patients | Method |
|---|
| Dens (CAPARES), 2000 | nisoldipine (40 mg/day) (n=308) vs. placebo (n=338) | | double blind Sample size: 308/338 Primary endpoint: FU duration: 6 months |
|
